How Modern Science Diagnoses and Treats Lung Cancer

Lung cancer remains one of the leading causes of cancer death worldwide, outpacing most other cancer types in the number of lives it takes each year. That burden has a clear historical explanation. Cigarette smoking is the single largest risk factor, a connection first established through careful epidemiological work more than seventy years ago by Richard Doll and Austin Bradford Hill. Their study was one of the earliest demonstrations that a common personal habit could be tied statistically to a specific disease, and it changed how researchers think about cancer risk more broadly.

Smoking remains the dominant, best-established risk factor today, which is why prevention and screening programs still focus heavily on current and former smokers. But lung cancer is not one disease. It is a label covering several biologically distinct cancers that are diagnosed, staged, and treated in different ways, and understanding those differences is the key to understanding modern lung cancer care.

Two Diseases Under One Name

Doctors split lung cancer into two broad categories that behave very differently. Roughly eight or nine out of every ten cases are non-small cell lung cancer, or NSCLC, a group that includes several subtypes and generally grows at a more measured pace. The remaining cases are small cell lung cancer, or SCLC, which tends to grow quickly and spread early, often before it causes symptoms a person would notice.

A useful comparison is two kinds of fire. NSCLC behaves more like a fire that, if caught early, can sometimes still be contained to one room. SCLC behaves more like a fire that has often already spread through the building by the time anyone smells smoke. That difference in behavior is why the two cancers are approached along almost entirely separate treatment paths, something this article returns to later.

Finding and Mapping the Disease

Because early lung cancer often causes no symptoms, catching it before it spreads matters enormously. A large randomized trial testing low-dose CT screening, which uses a lower radiation dose than a standard CT scan, found that screening high-risk current and former smokers reduced lung cancer deaths compared with no screening. That finding does not mean CT screening suits everyone. It applies specifically to people who meet defined risk criteria based on age and smoking history, a decision made together with a clinician rather than pursued independently.

Once a tumor is found, doctors need to know how far it has spread before choosing a treatment path. This is the role of TNM staging, a system describing tumor size, whether nearby lymph nodes are involved, and whether cancer has reached distant organs. Validated staging criteria now guide both prognosis and treatment choice across lung cancer types. A small, localized tumor caught early might be managed very differently from one that has already spread widely, where treatments reaching the whole body become necessary. Staging, in that sense, functions less like a label and more like a map for everything that follows.

Matching Treatment to Tumor Biology in NSCLC

For NSCLC, treatment increasingly depends on a tumor's molecular profile, not only its size and location. A meaningful share of NSCLC tumors carry a mutation in a gene called EGFR, which normally helps a cell receive signals telling it when to grow. The mutated version gets stuck in the "grow" position. Drugs known as tyrosine kinase inhibitors, or TKIs, are built to block that stuck signal, and tumors carrying these specific mutations tend to respond to TKIs in a way other NSCLC tumors generally do not. This connection, discovered in 2004, remains one of the clearest examples in oncology of matching a drug to a tumor's underlying biology rather than its location.

Among EGFR-targeted drugs, a newer option called osimertinib has shown better results as initial therapy than earlier-generation EGFR inhibitors, demonstrated in a randomized trial comparing the two approaches directly. That does not mean every patient with an EGFR mutation receives identical treatment; the specific mutation subtype, prior therapies, and other clinical factors all shape the decision.

A second gene, KRAS, is altered in many NSCLC tumors, but for decades its mutated protein was considered too smooth a surface for any drug to grip. A particular version of this mutation, called KRAS G12C, turned out to have a small pocket that chemists could finally exploit. Clinical trials have since shown that drugs built specifically for this mutation can shrink tumors that carry it. The gap between first identifying KRAS mutations in cancer and finally producing a drug able to act on them stretched across decades, a reminder that not every genetic discovery translates quickly into a treatment.

Harnessing the Immune System

Not every NSCLC tumor is defined by a single faulty growth gene. Many instead evade the immune system through a different trick: displaying a protein called PD-L1 on their surface, which signals nearby immune cells to stand down. Immune checkpoint inhibitors are drugs built to block that signal, freeing immune cells to recognize and attack the tumor. Trial evidence shows that tumors with high PD-L1 levels tend to respond better to these drugs than tumors with low or undetectable levels, which is why PD-L1 testing has become a routine step in planning treatment for advanced NSCLC. A high result raises the odds of benefit; it does not guarantee one, and some tumors with little detectable PD-L1 still respond to immunotherapy for reasons not yet fully understood.

For many patients with advanced non-squamous NSCLC whose tumors lack a targetable mutation, adding immunotherapy to standard chemotherapy has been shown to extend survival compared with chemotherapy given alone. That combination has become a common starting point for tumors without an EGFR mutation, a KRAS G12C mutation, or a similar targetable change.

Small Cell Lung Cancer: A Different Strategy

SCLC has historically been harder to treat than NSCLC, mainly because it grows and spreads so fast that it is often advanced by the time it is found. For years, chemotherapy alone was the standard approach for extensive-stage disease, with limited long-term improvement. More recently, adding immunotherapy to chemotherapy has been shown to extend survival in extensive-stage SCLC compared with chemotherapy alone, marking one of the first meaningful treatment advances for this cancer type in years. It has not closed the gap with NSCLC outcomes, but it has shifted what is considered standard first-line treatment for the disease.

What the Evidence Does and Does Not Settle

Taken together, the last two decades have turned lung cancer from a single disease treated one way into a collection of biologically defined cancers, each matched where possible to a therapy built for its specific drivers. Staging still anchors every treatment decision, screening still only helps the specific population it was tested in, and biomarkers like EGFR, KRAS G12C, and PD-L1 still describe probabilities of benefit rather than certainties.

Many NSCLC tumors carry none of these currently targetable changes, and SCLC still lacks the kind of biomarker-driven precision now available in NSCLC. Which patients will respond to a given targeted drug or immunotherapy, and for how long, remains an active area of research rather than a settled question. For any individual diagnosed with lung cancer, these findings describe population-level evidence; translating them into a specific treatment plan depends on a full evaluation by an oncology team.